Suono Bio gets Fujifilm investment for its second-generation drug delivery tech, names new CEO

Drugs and money
Fujifilm is investing in Suono Bio’s second-generation drug delivery technology. (Getty/LIgorko)

Japan’s Fujifilm is investing (PDF) in Suono Bio’s second-generation drug delivery technology that uses speedy, formulation-independent application of therapeutics that include biologics and gene therapies.

Terms and the amount of the investment by the Tokyo-based company weren’t disclosed.

Suono Bio uses tech developed in the MIT laboratory of Robert Langer. The technology has shown preclinical activity in a scope of diseases using a diverse set of therapeutics, the company said.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Fujifilm has deep technical expertise and offers the chance to accelerate our development by working closely with their scientists and engineers in the future,” Langer said in a statement.

In a separate announcement, Suono Bio announced that it named Lisa Ricciardi as chief executive. Prior to joining the company, Ricciardi has worked for a variety of organizations, including Pfizer, Medco, Foundation Medicine and Essex Woodlands.

“The addition of Lisa to the team marks an important milestone for Suono Bio, particularly as we prepare for our entry to the clinic,” Dr. Carl Schoellhammer, the company’s founding chief executive, said in a statement.

Schoellhammer will take on the role of COO and serve on the board.

Suggested Articles

WIRB-Copernicus launched a product aimed at upping the efficiency of clinical research operators at institutions and independent research sites.

Celgene is paying Exscientia $25 million up front in a three-year discovery deal for three programs in oncology and autoimmunity. reeled in $5 million in series A funding that it plans to use to accelerate lab deployment and expand other features.